--- title: "Tevogen (TVGN) news: offering and Nasdaq notice" url: "https://aibio.space/companies/tevogen/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "TVGN offering and Nasdaq notice news: Tevogen Bio Holdings sets up $50,000,000 at-the-market stock program with A.G.P.. Tevogen Inc." --- TVGN Tevogen Inc. NASDAQ · United States # Tevogen (TVGN) news TVGN offering and Nasdaq notice news Listings · 2026-09-30 ## [Tevogen regains compliance with Nasdaq Global Market listing rules](https://aibio.space/news/tevogen-regains-compliance-nasdaq-global-market-listing-rules/) Nasdaq confirmed on September 29, 2026 that Tevogen meets the $50 million minimum market value of listed securities rule. The company had $1.1 million of cash at June 30, 2026, after cash used in operations of $12.3 million in 2025. ## Latest Tevogen news 1. 2026-04-22 Listings [Tevogen Bio Holdings (now Tevogen Inc.) gets two Nasdaq deficiency notices on market value](https://aibio.space/news/tevogen-bio-holdings-now-tevogen-inc-gets-two-nasdaq-deficiency/) Tevogen received two Nasdaq notices in April 2026 saying it no longer meets the $50 million listed-securities market value requirement or the $15 million publicly held shares requirement. It has until October 13 and October 14, 2026 to regain compliance with each. 2. 2025-09-26 Listings [Tevogen Bio Holdings Inc. (now Tevogen Inc.) gets Nasdaq minimum bid price notice](https://aibio.space/news/tevogen-bio-holdings-inc-now-tevogen-inc-gets-nasdaq-minimum-bid-price/) Nasdaq told Tevogen Bio Holdings on September 23, 2025 that its shares had closed below $1.00 for 30 consecutive business days, giving it until March 23, 2026 to regain compliance. Its 2024 annual report said the company was relying on $8.0 million of grant funding it had not yet received. 3. 2025-07-03 Financings [Tevogen Bio Holdings sets up $50,000,000 at-the-market stock program with A.G.P.](https://aibio.space/news/tevogen-bio-holdings-sets-up-50-000-000-market-stock-program/) Tevogen can sell up to $50,000,000 of common stock through A.G.P./Alliance Global Partners, which is paid 3.0% of gross proceeds. The company's net tangible book value was negative $7.72 million at March 31, 2025, and buyers at the $1.25 reference price would face $1.07 a share of dilution. 4. 2025-04-01 Distress [Tevogen Bio Holdings (now Tevogen) delays 10-K, sees 2024 loss of about $13.7 million](https://aibio.space/news/tevogen-bio-holdings-now-tevogen-delays-10-k-sees-2024-loss-about-13-7/) Tevogen said a change in outside accounting providers in September 2024 left it needing more time. It will keep reporting material weaknesses in internal controls. ## Tevogen at a glance - **Ticker**: TVGN - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $1.1 million ### Related companies - [Organon & Co.](https://aibio.space/companies/organon/) NYSE: OGN - [Compass Therapeutics](https://aibio.space/companies/compass-therapeutics/) NASDAQ: CMPX - [Arcturus Therapeutics Holdings](https://aibio.space/companies/arcturus-therapeutics/) NASDAQ: ARCT - [MapLight Therapeutics](https://aibio.space/companies/maplight-therapeutics/) NASDAQ: MPLT - [Pyxis Oncology](https://aibio.space/companies/pyxis-oncology/) NASDAQ: PYXS - [Ardelyx](https://aibio.space/companies/ardelyx/) NASDAQ: ARDX - [Avalyn Pharma](https://aibio.space/companies/avalyn-pharma/) NASDAQ: AVLN - [Harrow](https://aibio.space/companies/harrow/) NASDAQ: HROW ### Also on NASDAQ - [Ernexa Therapeutics](https://aibio.space/companies/ernexa-therapeutics/) ERNA - [ADARx Pharmaceuticals](https://aibio.space/companies/adarx-pharmaceuticals/) ADRX - [Ligand Pharmaceuticals](https://aibio.space/companies/ligand-pharmaceuticals/) LGND - [MAXCYTE, INC.](https://aibio.space/companies/maxcyte/) MXCT - [Cuprina Holdings (Cayman)](https://aibio.space/companies/cuprina-cayman/) CUPR - [TScan Therapeutics](https://aibio.space/companies/tscan-therapeutics/) TCRX ## Tevogen annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$11.1 million](https://www.sec.gov/Archives/edgar/data/1860871/000149315226014326/) | [$31.0 million](https://www.sec.gov/Archives/edgar/data/1860871/000149315226014326/) | | Net income (loss) | [-$26.3 million](https://www.sec.gov/Archives/edgar/data/1860871/000149315226014326/) | [-$13.7 million](https://www.sec.gov/Archives/edgar/data/1860871/000149315226014326/) | | Cash from operations | [-$12.3 million](https://www.sec.gov/Archives/edgar/data/1860871/000149315226014326/) | [-$12.0 million](https://www.sec.gov/Archives/edgar/data/1860871/000149315226014326/) | | Cash and equivalents | [$0](https://www.sec.gov/Archives/edgar/data/1860871/000149315226014326/) | [$0](https://www.sec.gov/Archives/edgar/data/1860871/000149315226014326/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $1.1 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Tevogen Has Tevogen raised money recently? Our latest story on this, dated Jul 3, 2025: "Tevogen Bio Holdings sets up $50,000,000 at-the-market stock program with A.G.P.". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/tevogen-bio-holdings-sets-up-50-000-000-market-stock-program/). Has Tevogen received a Nasdaq deficiency notice? Our latest story on this, dated Apr 22, 2026: "Tevogen Bio Holdings (now Tevogen Inc.) gets two Nasdaq deficiency notices on market value". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/tevogen-bio-holdings-now-tevogen-inc-gets-two-nasdaq-deficiency/). What is the ticker symbol of Tevogen? Tevogen Inc. trades under the ticker TVGN on NASDAQ. Where is Tevogen listed? Tevogen Inc. is listed on NASDAQ. What is the SEC CIK of Tevogen? The SEC Central Index Key (CIK) for Tevogen Inc. is 1860871. Its filings are on SEC EDGAR. How many shares does Tevogen have outstanding? 6,511,540 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Tevogen listed under? Our directory records Tevogen Inc. under United States. What does Tevogen do? Our directory classifies Tevogen Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Tevogen? The ISIN recorded for Tevogen Inc. is US88165K2006. Does aibio.space cover Tevogen? aibio.space lists Tevogen Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Tevogen incorporated? SEC records list its state or country of incorporation as DE. Is Tevogen profitable? Tevogen Inc. reported a net loss of $26.3 million for the fiscal year ended Dec 31, 2025, and used $12.3 million of cash in operations, per its annual report to the SEC. How much does Tevogen spend on research and development? $11.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Tevogen have? $1.1 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Tevogen (TVGN) stock news? Our latest story on Tevogen, dated Sep 30, 2026: "Tevogen regains compliance with Nasdaq Global Market listing rules". Nasdaq confirmed on September 29, 2026 that Tevogen meets the $50 million minimum market value of listed securities rule. The company had $1.1 million of cash at June 30, 2026, after cash used in operations of $12.3 million in 2025. [Source](https://aibio.space/news/tevogen-regains-compliance-nasdaq-global-market-listing-rules/). ## Investor discussion: Tevogen Members talk about Tevogen (TVGN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Tevogen, newest first. Each line links the filing it comes from. 1. 2026-09-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1860871/000149315226045123/ex99-1.htm) 2. 2026-09-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1860871/000149315226042095/form8-k.htm) 3. 2026-04-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1860871/000149315226018590/form8-k.htm) 4. 2026-03-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1860871/000149315226012701/form8-k.htm) 5. 2026-03-04 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1860871/000149315226008786/ex99-1.htm) 6. 2026-02-25 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1860871/000149315226008065/form8-k.htm) 7. 2026-01-26 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1860871/000149315226003649/formdef14a.htm) 8. 2026-01-16 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1860871/000149315226002646/formpre14a.htm) 9. 2025-09-26 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1860871/000149315225015784/form8-k.htm) 10. 2025-07-03 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1860871/000164117225017863/form424b5.htm) 11. 2025-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1860871/000164117225001996/formnt10-k.htm) 12. 2024-11-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1860871/000149315224046269/formnt10-q.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:TVGN on TradingView](https://www.tradingview.com/symbols/NASDAQ-TVGN/). ## SEC filings and registration - **SEC name**: Tevogen Inc. - **CIK**: 1860871 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: TVGN (Nasdaq), TVGNW (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 15 INDEPENDENCE BOULEVARD, SUITE #210, WARREN, NJ, 07059 - **Phone**: 646-807-8832 - **Shares outstanding**: 6,511,540 as of 2026-08-10 (10-Q filed 2026-08-14) - **Former names**: Tevogen Bio Holdings Inc.; Semper Paratus Acquisition Corp ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1860871/000149315226045123/form8-k.htm) filed 2026-09-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1860871/000149315226042952/form8-k.htm) filed 2026-09-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1860871/000149315226042095/form8-k.htm) filed 2026-09-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1860871/000149315226040216/form8-k.htm) filed 2026-08-26 - [10-Q](https://www.sec.gov/Archives/edgar/data/1860871/000149315226038509/form10-q.htm) filed 2026-08-14 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1860871/000149315226035757/formdef14a.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1860871/000149315226035334/form8-k.htm) filed 2026-07-30 - [S-3](https://www.sec.gov/Archives/edgar/data/1860871/000149315226028495/forms-3.htm) filed 2026-06-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001860871), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Tevogen Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TVGN, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Tevogen Inc. - **Ticker**: TVGN - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US88165K2006 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-TVGN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/tevogen/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Tevogen (TVGN) news: offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/tevogen/